A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus
Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug
known as LY3532226 in participants with type 2 diabetes mellitus (T2DM). Blood tests will be
performed to check how much LY3532226 gets into the bloodstream and how long it takes the
body to eliminate it. This is a 2-part study and will last approximately 16 weeks excluding
screening period for each part, respectively.